Thu, May 15, 8:33 PM (34 days ago)
Tivic Health Systems, Inc. (TIVC) reported a challenging first quarter for 2025, with significant financial and operational uncertainties. The company's revenue decreased by 79% to $70,000, primarily due to reduced advertising spend and a focus on securing the Statera Licensing Agreement. Gross profit increased by 21% compared to the same period in 2024, driven by supply chain restructuring and lower logistics costs. Operating expenses saw mixed trends: research and development increased by $79,000 due to headcount-related costs, while sales and marketing expenses decreased by $326,000 due to reduced advertising spend. General and administrative expenses increased by $155,000, primarily due to legal and other fees. The company reported a net loss of $1.5 million, slightly higher than the previous year. Cash and cash equivalents decreased by $1.3 million, with negative cash flows from operations and investing activities. Tivic Health is focusing on its bioelectronic and biopharma programs, including the development of non-invasive medical devices and the advancement of its TLR5 program. The company is also pursuing various monetization strategies for its ClearUP product and is exploring strategic acquisitions and licensing opportunities. However, Tivic Health faces significant uncertainties, including the need for additional capital, regulatory approvals, and market volatility. The company's ability to continue as a going concern is in doubt, and it may need to raise additional funds to support its operations and growth plans.